| 897 |
Centers for Disease Control and Prevention |
Html |
en |
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2014 |
Carolyn B. Bridges, MD1, Tamera Coyne-Beasley, MD2, Advisory Committee on Immunization Practices (ACIP)*, ACIP Adult Immunization Work Group (Author affiliations at end of text). |
| North Carolina | 0.5516 |
| current low levels | 0.601357 |
| American Academy | 0.541782 |
| vaccine registries | 0.617143 |
| city immunization programs | 0.557173 |
| vaccination coverage | 0.587251 |
| Vaccine Advisory Committee | 0.693806 |
| Td/Tdap vaccine footnote | 0.689266 |
| adult immunization schedules | 0.640652 |
| pneumococcal conjugate vaccine | 0.661296 |
| influenza vaccine | 0.713585 |
| immunization schedule information | 0.589768 |
| meningococcal vaccine footnote | 0.692719 |
| vaccine 3-dose series | 0.665796 |
| inactivated influenza vaccine | 0.662832 |
| PCV13 vaccine row | 0.641854 |
| prior Hib vaccination | 0.618417 |
| adult immunization schedule | 0.580465 |
| Recommended Immunization Schedule | 0.65524 |
| influenza vaccine footnote | 0.709462 |
| zoster vaccine footnotes | 0.646597 |
| pneumococcal polysaccharide vaccine | 0.66407 |
| Hib vaccine recommendations | 0.772054 |
| pediatric immunization schedule | 0.558669 |
| vaccines | 0.796412 |
|
| immunization schedule | 0.708659 |
| interested health-care providers | 0.533465 |
| adults | 0.552094 |
| Noninfluenza vaccination coverage | 0.529645 |
| polysaccharide quadrivalent vaccines | 0.623733 |
| health-care providers | 0.577416 |
| HPV vaccine | 0.60158 |
| meningococcal vaccines | 0.603184 |
| adult vaccines | 0.646425 |
| Immunization Practices | 0.549934 |
| specific vaccines | 0.618203 |
| Hib infection | 0.532216 |
| American College | 0.619647 |
| immunization information systems | 0.584718 |
| Hib vaccine guidance | 0.727328 |
| Td vaccine | 0.603414 |
| hepatitis B vaccine | 0.656027 |
| Hib vaccine | 0.905602 |
| recombinant influenza vaccine | 0.661172 |
| Work Group | 0.58781 |
| vaccine footnote | 0.751949 |
| health-care provider | 0.534962 |
| ACIP recommendations | 0.714085 |
| vaccine footnotes | 0.649191 |
|
CLICK HERE |
| 4814 |
Centers for Disease Control and Prevention |
Html |
en |
Chronic Diseases and Mortality in Canadian Aboriginal Peoples: Learning From the Knowledge |
null |
| non-Aboriginal population | 0.419582 |
| Canada’s Aboriginal | 0.762834 |
| health equity | 0.549389 |
| Nations community | 0.499516 |
| health inequities | 0.436364 |
| health information | 0.433363 |
| unique social determinants | 0.520937 |
| social determinants | 0.622416 |
| M. Indigenous health | 0.504983 |
| urban Aboriginal adults | 0.612643 |
| health gap | 0.508954 |
| total urban cohort | 0.48825 |
| societal risk factors | 0.4685 |
| Manitoba First Nations | 0.491722 |
| urban Aboriginal cohort | 0.616637 |
| arthritis consult health | 0.5374 |
| risk factors | 0.541099 |
| mortality registry data | 0.487011 |
| urban non-Aboriginal Canadians | 0.513211 |
| on-reserve First Nations | 0.488985 |
| community engagement | 0.541663 |
| life expectancy | 0.661914 |
| health status | 0.586403 |
| Aboriginal women | 0.528306 |
|
| Aboriginal Peoples Survey | 0.643919 |
| chronic disease | 0.588195 |
| low plasma apolipoprotein | 0.47837 |
| non-Aboriginal mainstream | 0.416097 |
| main strategic directions.10 | 0.459909 |
| Self-reported arthritis | 0.415559 |
| joint publication initiative | 0.496084 |
| health knowledge | 0.433554 |
| national Aboriginal population | 0.615644 |
| Aboriginal Canadians | 0.517256 |
| conventional social determinants | 0.480445 |
| national community engagement | 0.486163 |
| aboriginal peoples | 0.968314 |
| urban centers | 0.500286 |
| Longitudinal Health Survey | 0.533257 |
| local community engagement | 0.479281 |
| chronic diseases | 0.579882 |
| lower life expectancy | 0.525356 |
| health | 0.650369 |
| high cardiovascular risk | 0.483866 |
| Aboriginal populations | 0.607455 |
| common medical condition | 0.479604 |
| health center | 0.434475 |
| national survey data | 0.475251 |
|
CLICK HERE |
| 6983 |
Centers for Disease Control and Prevention |
Html |
en |
Global Health - Sierra Leone |
CDC began working in Sierra Leone in 2008 and supports laboratory and surveillance capacity building activities for HIV and other infectious diseases. |
| CDC Foundation | 0.537277 |
| U.S. CDC | 0.934353 |
| 2014-2015 Ebola response | 0.468765 |
| 5-year immunization plan | 0.390789 |
| infectious disease threats | 0.373142 |
| AIDS Relief | 0.383123 |
| antimicrobial resistance | 0.376909 |
| Emergency Operations Centers | 0.371439 |
| national public health | 0.55138 |
| extensive global health | 0.428695 |
| permanent CDC Country | 0.660504 |
| Emergency Plan | 0.390637 |
| standard operating procedures | 0.358404 |
| World Health Organization | 0.422964 |
| vaccine coverage data | 0.367658 |
| MoHS immunization activities | 0.438689 |
| emergency management | 0.37982 |
| public health emergencies | 0.414296 |
| national oral polio | 0.366406 |
| 5-year national laboratory | 0.395251 |
| Emergency Operations | 0.374957 |
| laboratory systems | 0.379283 |
| public health management | 0.445759 |
| Health Security Agenda | 0.562091 |
|
| public health information | 0.416784 |
| GHSA action packages | 0.36874 |
| largest outbreak response | 0.430187 |
| Global Health Security | 0.73615 |
| Epidemiology Training Program | 0.371533 |
| Sierra Leone | 0.814147 |
| U.S. President | 0.403089 |
| biometrics-based immunization tracking | 0.384314 |
| nationwide measles vaccine | 0.369103 |
| Infant mortality rate | 0.391838 |
| new laboratory tests | 0.374518 |
| highest number | 0.38021 |
| public health | 0.682214 |
| Health Security efforts | 0.431873 |
| World Health Statistics | 0.432591 |
| infection prevention | 0.369913 |
| Central Public Health | 0.421044 |
| flaccid paralysis review | 0.367846 |
| MoHS disease surveillance | 0.445655 |
| public health Emergency | 0.442879 |
| Relief building laboratory | 0.410229 |
| West Africa | 0.38017 |
| public health data | 0.417111 |
| CDC technical assistance | 0.613478 |
|
CLICK HERE |
| 7551 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Histoplasmosis Outbreak Among Day Camp Attendees - Nebraska, June 2012 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| logistic regression model | 0.72839 |
| respiratory illness outbreaks | 0.795626 |
| respiratory illness cluster | 0.806283 |
| County Health Department | 0.780458 |
| Douglas County | 0.747162 |
| original MMWR paper | 0.731792 |
| U.S. Government Printing | 0.729282 |
| endemic areas | 0.748107 |
| Human Services | 0.803307 |
| common fungal infection | 0.746769 |
| test p-value | 0.745024 |
| MMWR HTML versions | 0.732749 |
| U.S. Department | 0.719179 |
| Douglas County Dept | 0.717716 |
| camp administrators | 0.699555 |
| dirt floors | 0.734013 |
| wilderness skill training | 0.726182 |
| Laboratory-confirmed histoplasmosis | 0.732033 |
| Bryan F. Buss | 0.722233 |
| picnic tables | 0.976993 |
| electronic PDF version | 0.728302 |
| Histoplasma capsulatum antigen | 0.766038 |
| recreation division | 0.733171 |
| Zoonotic Infectious Diseases | 0.721946 |
|
| histoplasmosis | 0.746493 |
| Benjamin J. Park | 0.725592 |
| campsites | 0.810189 |
| personal protective equipment | 0.732735 |
| Career Epidemiology Field | 0.723355 |
| potentially contaminated areas | 0.735795 |
| additional symptom | 0.738612 |
| probable infection source | 0.730191 |
| camp arrival | 0.704023 |
| separate Internet-based questionnaire | 0.734579 |
| camp counselor | 0.770558 |
| campsite assignments | 0.816981 |
| Public Health Preparedness | 0.736631 |
| bat droppings | 0.758994 |
| camp attendees | 0.753485 |
| case definition | 0.740323 |
| Cochran-Armitage test p-value | 0.735006 |
| referent group | 0.729925 |
| original paper copy | 0.72183 |
| exact test p-value | 0.739478 |
| camp activities | 0.82193 |
| bat guano | 0.892122 |
| Kristin Yeoman | 0.74041 |
|
CLICK HERE |
| 10395 |
Centers for Disease Control and Prevention |
Html |
en |
DHDSP Data Trends and Maps Indicator Categorizations'DHDSP'CDC |
DHDSP Data Trends and Maps Help |
| Cardiovascular Diseases | 0.844935 |
| Risk Factors | 0.792209 |
| main categories | 0.521361 |
| following priority areas | 0.905055 |
| ABCS | 0.297158 |
| number | 0.251086 |
| Priority Indicators | 0.941759 |
|
| priority indicator | 0.668559 |
| AHA | 0.288143 |
| Cardiovascular Health Metrics | 0.837426 |
| subcategories | 0.660988 |
| Healthy People | 0.491508 |
| Goals | 0.249955 |
| Risk Factors category | 0.759515 |
|
CLICK HERE |
| 11352 |
Centers for Disease Control and Prevention |
Html |
en |
Recommendations for Chemical Protective Clothing: Database |
null |
| dry chemical | 0.463092 |
| direct skin contact | 0.554055 |
| Krister Forsberg | 0.464914 |
| CPC recommendations | 0.491725 |
| contact dermatitis | 0.477274 |
| direct skin hazard | 0.526037 |
| standard temperature conditions | 0.500217 |
| competent industrial hygienist | 0.497885 |
| recommendations | 0.493616 |
| general recommendations | 0.47469 |
| Occupational Safety | 0.461872 |
| standard test method | 0.509114 |
| NIOSH policy | 0.475139 |
| direct contact | 0.510102 |
| systemic toxic effects | 0.515574 |
| breakthrough time | 0.528538 |
| chemical protective clothing | 0.725398 |
| contamination problem | 0.47079 |
| wet skin | 0.469202 |
| skin protection | 0.518482 |
| chemicals | 0.508819 |
| National Institute | 0.465958 |
| Pocket Guide | 0.665423 |
|
| Chemical Abstract Service | 0.506558 |
| chemical manufactures | 0.469093 |
| Protective Clothing database | 0.568771 |
| protective clothing supplier | 0.542832 |
| protective clothing | 0.916805 |
| inadvertent contamination | 0.468503 |
| Quick Selection Guide | 0.515581 |
| significant dermal hazard | 0.517101 |
| unprotected skin | 0.597445 |
| NIOSH Pocket Guide | 0.529011 |
| dermal hazard | 0.585795 |
| Protective Clothing Materials | 0.552873 |
| dermal hazard potential | 0.534526 |
| faster breakthrough | 0.480324 |
| permeation resistance | 0.562551 |
| adverse effects | 0.463473 |
| gaseous contact | 0.468741 |
| skin contact | 0.571288 |
| steady state permeation | 0.55673 |
| designation | 0.462388 |
| protective clothing manufacturers | 0.546203 |
| Continuous Contact | 0.466147 |
| protective barrier | 0.491657 |
|
CLICK HERE |
| 11447 |
Centers for Disease Control and Prevention |
Html |
en |
CDC's Funding |
CDC’s Funding |
| special emphasis | 0.479504 |
| germs | 0.209 |
| health threats | 0.966093 |
| ANTIBIOTIC RESISTANCE | 0.553468 |
| INFECTIOUS OUTBREAKS | 0.599189 |
| simple infections | 0.493446 |
| highest rates | 0.487103 |
| PRESCRIPTION PAINKILLER DRUG | 0.858224 |
|
| disease detection technologies | 0.836858 |
| FY | 0.799339 |
| prescription drug abuse | 0.820542 |
| new health threats | 0.898105 |
| response | 0.252458 |
| ADVANCED MOLECULAR DETECTION | 0.916094 |
| OVERDOSE EPIDEMIC | 0.566379 |
| alarmingly growing epidemic | 0.924676 |
|
CLICK HERE |
| 11464 |
Centers for Disease Control and Prevention |
Html |
en |
Immunization & Respiratory Diseases |
CDC protects all Americans from disease, disability, and death through immunization and by controlling respiratory and other preventable diseases. |
| North Carolina | 0.562545 |
| CDC | 0.639298 |
| 23-case outbreak | 0.596755 |
| Helped partners | 0.595564 |
| effective outbreak field | 0.711628 |
| epidemiology expertise | 0.575055 |
| international partners | 0.55534 |
| local communities | 0.575058 |
| active influenza season | 0.768758 |
| children | 0.455616 |
| measles outbreaks | 0.61003 |
| new H7N9 virus | 0.717492 |
| global health threats | 0.764766 |
| public health decisions | 0.716102 |
| bird flu viruses | 0.691157 |
| severe cases | 0.567389 |
| novel influenza control | 0.77536 |
| potential vaccine virus | 0.725953 |
| virus spreads | 0.572151 |
| urgent health threats | 0.752179 |
| health threats | 0.908743 |
| viral disease threats | 0.763239 |
| avian influenza viruses | 0.742073 |
| birds | 0.44661 |
| H7N9 vaccine | 0.593644 |
|
| H7N9 influenza | 0.640908 |
| states | 0.456752 |
| MERS CoV | 0.601661 |
| public health threats | 0.772421 |
| close contact | 0.554546 |
| studies | 0.445795 |
| H7N9 diagnostic tests | 0.703381 |
| 2M | 0.441721 |
| public health | 0.891336 |
| Middle East Respiratory | 0.72217 |
| CDC scientists | 0.63194 |
| electronic health records | 0.723357 |
| genetic sequences | 0.55456 |
| people | 0.510642 |
| immunization information technologies | 0.722226 |
| whooping cough | 0.587908 |
| human infections | 0.682652 |
| new virus | 0.575221 |
| Vaccine-Preventable Diseases Centers | 0.712695 |
| H7N9 strains | 0.579128 |
| late 1980s | 0.556762 |
| international leadership | 0.575383 |
| localized outbreaks | 0.575338 |
| China’s response | 0.573469 |
|
CLICK HERE |
| 12686 |
Centers for Disease Control and Prevention |
Video |
en |
Global Disease Detectives |
CDC global health leadership brings the world's leading public health experts to a Guatemala cave, where rabid bats threaten human health. Elsewhere, CDC community workers keep a health watch over Kenya's poor; while in China, CDC scientists protect babies from a mysterious outbreak. These examples of CDC at work in the world help protect America and all from disease threats that respect no borders.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at http://www.cdc.gov/cdctv/DiseaseDetectives |
| Global Disease Detectives | 0.934136 |
|
|
CLICK HERE |
| 15989 |
Centers for Disease Control and Prevention |
Html |
en |
Thank You, CDC Influenza Molecular Diagnostic Performance Evaluation Exercise Enrollment |
This website is intended to facilitate technical support for domestic U.S. and international public health and research institutions performing influenza laboratory surveillance and/or research. |
| Influenza Diagnostic Testing | 0.368017 |
| Flu Illness | 0.465741 |
| Flu Viruses | 0.578597 |
| Flu Vaccines | 0.718731 |
| U.S. Influenza Surveillance | 0.359587 |
| Vaccine Benefits | 0.27901 |
| Prevent Flu | 0.528704 |
| Influenza Testing Results | 0.406465 |
| Flu Good Health | 0.518459 |
| Influenza Viruses | 0.409303 |
| Seasonal Influenza Vaccine | 0.650023 |
| Quadrivalent Influenza Vaccine | 0.557727 |
| Intradermal Influenza | 0.318457 |
| Flu Adults | 0.479376 |
| Flu Activity | 0.465305 |
| Influenza Pandemic Virus | 0.374647 |
| Flu Vaccine | 0.897973 |
| (Flu) | 0.791257 |
| ) Vaccination | 0.578942 |
| Influenza Vaccines | 0.452865 |
| United States Flu | 0.499946 |
| Vaccine Safety Vaccine | 0.502287 |
| Antiviral Drugs Antiviral | 0.291442 |
| Influenza Viruses Types | 0.401434 |
| Flublok Seasonal Influenza | 0.382795 |
|
| Vaccination Flu Vaccination | 0.56543 |
| High-Dose Seasonal Influenza | 0.385031 |
| Control Influenza Transmission | 0.339302 |
| Flu Antiviral Drugs | 0.723605 |
| CDC International Flu | 0.511398 |
| CDC Influenza Molecular | 0.488287 |
| Distribution Vaccine Supply | 0.301129 |
| Prevent Flu Preventive | 0.505969 |
| Flu Vaccine Recommendation | 0.657322 |
| Flu Treatment | 0.485735 |
| Influenza Vaccination Clinic | 0.38851 |
| Flu News | 0.415385 |
| Flu Complications | 0.446476 |
| Flu Season Flu | 0.971451 |
| Diagnosis Flu Symptoms | 0.509214 |
| Flu Vaccine Safety | 0.747052 |
| Cell-Based Flu Vaccines | 0.566465 |
| Flu Season Current | 0.534751 |
| Vaccine Virus Selection | 0.299231 |
| Vaccine Effectiveness | 0.325266 |
| Flu Vaccines Work | 0.579262 |
| Influenza Vaccine Doses | 0.551841 |
| Past Flu Seasons | 0.509974 |
| Influenza 2015-2016 Season | 0.398568 |
|
CLICK HERE |